FDA clears DuchesnayUSA’s Diclegis for treatment of NVP
The FDA granted Diclegis Pregnancy Category A status as drug has not shown an increased risk to an unborn baby during pregnancy during controlled studies. The active ingredients
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
New facility for Bio-Manguinhos will use iBio’s plant-based protein expression technology, iBioLaunch, and GE Healthcare’s expertise in process design and start-to-finish biopharmaceutical and vaccine manufacturing technologies. GE Healthcare